NHS London Branded Medicines - Tranche B - September 2023
A Contract Award Notice
by NHS ENGLAND
- Source
- Find a Tender
- Type
- Framework (Goods)
- Duration
- not specified
- Value
- £1
- Sector
- HEALTH
- Published
- 08 Aug 2023
- Delivery
- not specified
- Deadline
- n/a
Related Terms
Location
United Kingdom: Please refer to Document No. 03, Schedule 8 in the ITO Documents for the list of Purchasing Points
1 buyer
- NHS England Leeds
36 suppliers
- Biogen Berkshire
- Celltrion Healthcare Slough
- Sandoz Surrey
- Zentiva Pharma Felsted
- Takeda London
- Orifarm Hertfordshire
- Teva Castleford
- CST Pharma Walsall
- Roche Products Welwyn Garden City
- Kent Pharma Kent
- Pfizer Surrey
- Mylan Hatfield
- Janssen Cilag High Wycombe Bucks
- Eli Lilly Hampshire
- Ipsen Slough
- Almirall Uxbridge
- Aventis Pharma Berkshire
- Merck Serono Middlesex
- Novartis Pharmaceuticals London
- Novo Nordisk London Gatwick Airport
- Typharm Norwich
- Gilead Sciences High Holborn
- Neon Healthcare Hertfordshire
- Bayer Berkshire
- Thornton & Ross Huddersfield
- Glaxosmithkline London
- Accord Devon
- Merck Sharpe & Dohme London
- Astrazeneca London
- Abbvie Berks
- Organon Pharmaceuticals London
- Sun Pharma Uxbridge
- Gedeon Richter London
- Galapagos Biotech Uxbridge
- Sobi Swedish Orphan Biovitrum Cambridgeshire
- Ucb Pharma Berkshire
Description
Project Title: NHS London Branded Medicines - Tranche B - September 2023Offer reference number: CM/PHR/22/5677CM/PHR/22/5677/01 - NHS Framework for London Branded Medicines - Tranche B. Period of framework: 1 September 2023 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 monthsCM/PHR/22/5677/02 - NHS Framework for London Branded Medicines - Annual Tranche. Period of framework: 1 September 2023 to 31 August 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.
Lot Division
| 1 | CM/PHR/22/5677/01 - NHS London Branded Medicines - Tranche B Lot 1 CM/PHR/22/5677/01 - NHS Framework for London Branded Medicines - Tranche B. Period of framework: 1 September 2023 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents |
| 2 | CM/PHR/22/5677/02 - NHS London Branded Medicines - Tranche B Lot 2 CM/PHR/22/5677/02 - NHS Framework for London Branded Medicines - Annual Tranche. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents |
Award Detail
| 1 | Biogen (Berkshire)
|
| 2 | Celltrion Healthcare (Slough)
|
| 3 | Sandoz (Surrey)
|
| 4 | Zentiva Pharma (Felsted)
|
| 5 | Takeda (London)
|
| 6 | Orifarm (Hertfordshire)
|
| 7 | Teva (Castleford)
|
| 8 | CST Pharma (Walsall)
|
| 9 | Roche Products (Welwyn Garden City)
|
| 10 | Kent Pharma (Kent)
|
| 11 | Pfizer (Surrey)
|
| 12 | Mylan (Hatfield)
|
| 13 | Janssen Cilag (High Wycombe Bucks)
|
| 14 | Eli Lilly (Hampshire)
|
| 15 | Ipsen (Slough)
|
| 16 | Almirall (Uxbridge)
|
| 17 | Aventis Pharma (Berkshire)
|
| 18 | Merck Serono (Middlesex)
|
| 19 | Novartis Pharmaceuticals (London)
|
| 20 | Novo Nordisk (London Gatwick Airport)
|
| 21 | Typharm (Norwich)
|
| 22 | Gilead Sciences (High Holborn)
|
| 23 | Neon Healthcare (Hertfordshire)
|
| 24 | Bayer (Berkshire)
|
| 25 | Thornton & Ross (Huddersfield)
|
| 26 | Glaxosmithkline (London)
|
| 27 | Accord (Devon)
|
| 28 | Celltrion Healthcare (Slough)
|
| 29 | Takeda (London)
|
| 30 | Orifarm (Hertfordshire)
|
| 31 | Merck Sharpe & Dohme (London)
|
| 32 | Teva (Castleford)
|
| 33 | Roche Products (Welwyn Garden City)
|
| 34 | Astrazeneca (London)
|
| 35 | Pfizer (Surrey)
|
| 36 | Abbvie (Berks)
|
| 37 | Janssen Cilag (High Wycombe Bucks)
|
| 38 | Eli Lilly (Hampshire)
|
| 39 | Organon Pharmaceuticals (London)
|
| 40 | Sun Pharma (Uxbridge)
|
| 41 | Aventis Pharma (Berkshire)
|
| 42 | Gedeon Richter (London)
|
| 43 | Novartis Pharmaceuticals (London)
|
| 44 | Galapagos Biotech (Uxbridge)
|
| 45 | Sobi Swedish Orphan Biovitrum (Cambridgeshire)
|
| 46 | Ucb Pharma (Berkshire)
|
Award Criteria
| price | _ |
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
- Options are available.
Other Information
** PREVIEW NOTICE, please check Find a Tender for full details. **
Reference
- ocds-h6vhtk-03b23b
- FTS 023090-2023